SLC5A2 and Polyuria: Furthermore, in the comparison between the Tofo Group and the Other SGLT2-I Group, the latter showed a significantly higher incidence of nocturnal polyuria (p = 0.043).<h4>Conclusions</h4>Tofogliflozin is less likely to exacerbate nocturnal polyuria compared to other SGLT2 inhibitors.